5:04 PM
 | 
Nov 07, 2012
 |  BC Extra  |  Clinical News

Rhucin meets Phase III HAE endpoint

Pharming Group N.V. (Euronext:PHARM) and partner Santarus Inc. (NASDAQ:SNTS) reported top-line data showing that a single IV infusion of 50 units/kg Rhucin conestat alfa met the primary endpoint of reducing median time to beginning of symptom relief vs. placebo in the Phase III...

Read the full 206 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >